Chad Briscoe and Jim McNally talk with Emmy-winning journalist and producer Charles Sabine on this episode of Molecular Moments. Their discussion centers around rare diseases, gene therapy and Huntington's Disease (HD). Charles, a carrier of the HD gene who has lost several immediate family members to the disease, is an ardent advocate for patients and families suffering from rare degenerative diseases.

From covering war zones to becoming a gene therapy patient, they discuss Charles’ career with MSNBC, his subsequent coverage of the Bosnian War, and his Emmy-winning coverage of the Romanian revolution. He also shared about his family’s medical issues, including his discovery that his father, uncle, and brother were all HD gene carriers. His father was one of the first people to be tested genetically for the disease in 1993. 

Jim, Chad, and Charles discuss the possibility of gene therapies halting further disease development rather than doctors prescribing drugs for a lifetime. Additionally, the trio discuss the boom in gene therapies, the pros and cons of genetic testing, and how rare disease patients are generally underserved in the biotech industry.

 

Chad Briscoe and Jim McNally talk with Emmy-winning journalist and producer Charles Sabine on this episode of Molecular Moments. Their discussion centers around rare diseases, gene therapy and Huntington's Disease (HD). Charles, a carrier of the HD gene who has lost several immediate family members to the disease, is an ardent advocate for patients and families suffering from rare degenerative diseases.
From covering war zones to becoming a gene therapy patient, they discuss Charles&rsquo; career with MSNBC, his subsequent coverage of the Bosnian War, and his Emmy-winning coverage of the Romanian revolution. He also shared about his family&rsquo;s medical issues, including his discovery that his father, uncle, and brother were all HD gene carriers. His father was one of the first people to be tested genetically for the disease in 1993.&nbsp;
Jim, Chad, and Charles discuss the possibility of gene therapies halting further disease development rather than doctors prescribing drugs for a lifetime. Additionally, the trio discuss the boom in gene therapies, the pros and cons of genetic testing, and how rare disease patients are generally underserved in the biotech industry.
&nbsp;

Welcome to the Molecular Moments podcast hosted by the scientific experts at BioAgilytix Labs! Whether you’re curious about what goes on at BioAgilytix or about the folks behind the lab coats, we’ve found a way to bring biologics closer to home. Each week, we chat with global experts, colleagues, and thought leaders who influence the pharmaceutical industry in biotherapeutics and beyond.

Welcome to the Molecular Moments podcast hosted by the scientific experts at BioAgilytix Labs! Whether you’re curious about what goes on at BioAgilytix or about the folks behind the lab coats, we’ve found a way to bring biologics closer to home. Each week, we chat with global experts, colleagues, and thought leaders who influence the pharmaceutical industry in biotherapeutics and beyond.

Molecular Moments Podcast

Welcome to the Molecular Moments podcast hosted by the scientific experts at BioAgilytix Labs! Whether you’re curious about what goes on at BioAgilytix or about the folks behind the lab coats, we’ve found a way to bring biologics closer to home. Each week, we chat with global experts, colleagues, and thought leaders who influence the pharmaceutical industry in biotherapeutics and beyond.

Advertisement